LIGAND PHARMACEUTICALS INC

LGND
About the company

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, develops and licenses biopharmaceutical assets worldwide. It offers Pradefovir, Posaconazole, Voriconazole, CAPVAXIVE, NOXAFIL, MenFive, and ZELSUVMI for infectious disease; EVOMELA and KYPROLIS for multiple myeloma; FILSPARI for the treatment of immunoglobulin a nephropathy; PNEUMOSIL, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia in children; and QARZIBA to treat neuroblastoma.

Country: United StatesPrice: $308.79Market Cap: $6.2B

Investment snapshot

12%positive consensus
Scored 1d ago

Positive

2

BUY / PASS

Neutral / negative

3 / 11

NEUTRAL / FAIL

Median fair value

$72.39

-76.6% vs price

Models with upside

0 / 17

Positive margin of safety

Strongest signal

5 of 8 pass — Graham, Lynch and Dreman object

Key risk

No clean pass — all 13 investors flag at least one valuation criterion

Framework analysis

VerdictMeaning
BUYPositive purchase signal: the framework's buy requirements are met.
PASSThe company clears the framework's checklist or screen, but the framework does not produce a buy signal. For valuation frameworks this often means margin of safety is missing, insufficient, or unavailable; some screen-only frameworks have no intrinsic-value BUY state.
NEUTRALNeither a positive nor negative conclusion. It does not mean to hold an existing position.
FAILThe company does not clear the framework's requirements.
RankedRanked strategies do not use PASS: selected cohort is BUY, outside the cohort is FAIL, and unranked is NEUTRAL.

Current investor scores use trailing 12-month flows and the latest balance sheet where supported. Multi-year and EPS tests retain annual history; each framework shows its financial basis below. Intrinsic values use annual financials.

MetricGraham

Defensive Value

Buffett

Quality Compounder

Lynch

GARP

Greenblatt

Magic Formula

Piotroski

F-Score

Dreman

Contrarian Value

Munger

Quality Focus

Pabrai

Dhandho Framework

Akre

Three-Legged Stool

Marks

Risk-Aware Value

Ackman

Activist Value

Templeton

Global Bargain Hunter

Sleep

Scale Economies Shared

Asness

Systematic Factors

Neff

Low-P/E Total Return

Schloss

Asset-Value Discipline

O'Shaughnessy

Systematic Factor Composite

VerdictFAILFAILFAILFAIL · Rank #1774 (Top 57.3%)PASSFAILFAILFAILFAILFAILPASSFAILNEUTRALNEUTRALFAILFAILNEUTRAL
Score
AnalysisChecking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…
Intrinsic Value (annual)N/AN/AN/AN/AN/AN/A
Margin of Safety-268.1%-230.3%-202.4%-7600.5%N/A-597.8%-591.1%-142.2%-422.3%-326.6%-251.5%-911.1%N/AN/AN/AN/AN/A
Financial Basis

TTM ended 2026-09-30 · Balance sheet at 2026-09-30 · Annual history · FY 2025

Latest source filing: 2026-10-30

Score computed: 2026-11-14

Annual history · FY 2025 · TTM ended 2026-09-30

Latest source filing: 2026-10-30

Score computed: 2026-11-14

Annual history · FY 2025 · Balance sheet at 2026-09-30 · TTM ended 2026-09-30 vs 2025-09-30 · TTM ended 2026-09-30

Latest source filing: 2026-10-30

Score computed: 2026-11-14

TTM ended 2026-09-30

Latest source filing: 2026-10-30

Score computed: 2026-11-14

Annual history · FY 2025

Latest source filing: 2026-02-27

Score computed: 2026-11-14

Annual history · FY 2025 · TTM ended 2026-09-30 · Balance sheet at 2026-09-30 · Market data at 2026-11-01

Latest source filing: 2026-10-30

Score computed: 2026-11-14

Qualitative assessment · Annual history · FY 2025 · TTM ended 2026-09-30 · Balance sheet at 2026-09-30

Latest source filing: 2026-10-30

Score computed: 2026-11-14

Qualitative assessment · Annual history · FY 2025

Latest source filing: 2026-02-27

Score computed: 2026-11-14

Annual history · FY 2025 · Qualitative assessment · TTM ended 2026-09-30 · Balance sheet at 2026-09-30

Latest source filing: 2026-10-30

Score computed: 2026-11-14

Annual history · FY 2025 · TTM ended 2026-09-30 · Qualitative assessment

Latest source filing: 2026-10-30

Score computed: 2026-11-14

Annual history · FY 2025 · TTM ended 2026-09-30 · Balance sheet at 2026-09-30 · Market data at 2026-11-01

Latest source filing: 2026-10-30

Score computed: 2026-11-14

Annual history · FY 2025 · Price history 2025-01-01–2026-11-01 · Balance sheet at 2026-09-30

Latest source filing: 2026-10-30

Score computed: 2026-11-14

Annual history · FY 2025 · Qualitative assessment

Latest source filing: 2026-02-27

Score computed: 2026-11-14

TTM ended 2026-09-30 · Balance sheet at 2026-09-30 · Price history 2025-01-01–2026-11-01 · Annual history · FY 2025

Latest source filing: 2026-10-30

Score computed: 2026-11-14

Annual history · FY 2025 · TTM ended 2026-09-30

Latest source filing: 2026-10-30

Score computed: 2026-11-14

Annual history · FY 2025 · Balance sheet at 2026-09-30

Latest source filing: 2026-10-30

Score computed: 2026-11-14

TTM ended 2026-09-30 · Annual history · FY 2025 · Price history 2025-01-01–2026-11-01

Latest source filing: 2026-10-30

Score computed: 2026-11-14

Where It Passes

  • Growth63% pass✓ 8✗ 5▾

    5 of 8 pass — Graham, Lynch and Dreman object

    EPS Growth (3-yr avg, 10-yr window)
    ✗Graham>= 33% growth
    Basic earnings-growth PEG (dividends excluded)3.02
    ✗Lynch< 1.0 (ideally < 0.5)
    3-5 Year EPS CAGR16.7%
    ✓Lynch15-30% (Fast Grower); > 0% to pass
    Inventory Growth vs Revenue GrowthInv: 21.9% vs Rev: 1.0%
    ✗LynchInventory growth < Revenue growth
    EPS Growth Direction
    ✗DremanPositive over recent years
    EPS CAGR
    ✗Dreman> 5% annualized
    Positive Net Income Frequency12/19 years positive
    ✓MarksPositive net income in >= 7 of last 10 years
    3yr Median Revenue Growth27.3%
    ✓Ackman>= 5%
    Positive EPS Growth Frequency3/5 years with positive EPS growth
    ✓AckmanPositive EPS growth in >= 3 of last 5 years
    5-Year EPS CAGR16.7% CAGR over 4 years
    ✓Templeton> 0% (5-year EPS CAGR)
    Revenue growth vs. gross and operating margin trendrevenue up, operating margin 9.1% -> 15.3%
    ✓SleepRevenue rising; gross margin flat or falling; operating margin holding
    5-year Revenue CAGR10.4%
    ✓SleepCAGR > 7%
    3-5 Year Diluted EPS CAGR16.7% over 4 years
    ✓Neff7%-20% annualized

Where It Falls Short

  • Valuation0% pass✓ 1✗ 27▾

    No clean pass — all 13 investors flag at least one valuation criterion

    Price / 3-yr avg EPS104.7x
    ✗Graham<= 15x
    Price-to-Book Ratio6.1x
    ✗Graham<= 1.5x
    P/E x P/B633.60
    ✗Graham<= 22.5
    Basic earnings-growth PEG (dividends excluded)3.02
    ✗Lynch< 1.0 (ideally < 0.5)
    EBIT / Enterprise Value0.3%
    ✗Greenblatt> 10%
    Earnings Yield + ROC AssessmentEY=0.3%, ROC=4.8%
    ✗GreenblattBoth EY > 10% and ROC > 25%
    Price / EPS50.4x
    ✗Dreman< 12x✗Templeton< 12x (fixed ceiling; proxy for the market's cheapest 40%)
    Price / (CFO / Shares)124.8x
    ✗Dreman< 8x
    Price / Book Value per Share6.1x
    ✗Dreman< 1.2x✗Templeton< 1.5x✗SchlossP/B <= 0.80x (app cutoff)
    Valuation ReasonablenessP/E=50.4x, OE Yield=2.6%
    ✗MungerP/E < 25 or Owner Earnings Yield > 5%
    P/E or FCF YieldP/E=50.4x, FCF Yield=0.8%
    ✗PabraiP/E < 15 or FCF Yield > 10%
    P/B or P/E vs. Historical AverageP/E=50.4x, P/B=6.1x
    ✗MarksP/E < 15 or P/B < 2.0
    Discount to Intrinsic Value-597.8% (IV=$44.25 vs Price=$308.79)
    ✗Marks>= 20% below intrinsic value
    Price / FCF per Share125.9x
    ✗Ackman<= 25
    Price vs. Trailing Low302% of trailing low ($102.19)
    ✗Templeton<= 120% of trailing low (certified split-adjusted live window)
    Net income / market capitalization+0.83%; #3022/6340 (top 47.7%)
    ✗AsnessTop 30% of eligible cross-section✗OshaughnessyTop 10% of eligible cross-section
    Positive book equity / market capitalization+0.1557; #4434/6449 (top 68.8%)
    ✗AsnessTop 30% of eligible cross-section
    Price / Diluted EPS50.4x
    ✗NeffP/E <= 15x (app proxy for a P/E 40%-60% below the market)
    (EPS CAGR % + Dividend Yield %) / P/E
    ✗Neff> 0.7 (Neff's published traditional edge)
    Price / Tangible Book Value per Share8.92x
    ✗SchlossP/TBV <= 1.00x (app cutoff)
    Book Value per Share Change+15.6%
    ✓SchlossLatest BVPS >= earliest BVPS over >= 3 years (app rule)
    Revenue / market capitalization+0.0411; #4628/5247 (top 88.2%)
    ✗OshaughnessyTop 10% of eligible cross-section
    (Operating cash flow - capex) / market capitalization+1.47%; #2330/4519 (top 51.6%)
    ✗OshaughnessyTop 10% of eligible cross-section
    Trailing six-month price return through the evaluation date+33.12%; #954/6202 (top 15.4%)
    ✗OshaughnessyTop 10% of eligible cross-section
  • Efficiency0% pass✓ 1✗ 10▾

    No clean pass — all 8 investors flag at least one efficiency criterion

    Current Ratio1.22
    ✗Graham>= 2.0
    ROIC (3-5 yr avg)2.1%
    ✗Buffett> 10%
    ROIC - WACC-7.9%
    ✗BuffettPositive (WACC = 10%)
    EBIT / (NWC + Net Fixed Assets)4.8%
    ✗Greenblatt> 25%
    Current Ratio Change YoY8.93 -> 22.23
    ✓PiotroskiIncreased YoY
    Revenue / Total Assets Change YoY0.18x -> 0.17x
    ✗PiotroskiImproved YoY
    Current Assets / Current Liabilities1.22
    ✗Dreman> 1.5
    Return on Invested Capital0.9%
    ✗Munger> 15%
    ROIC (high and growing)FY2023: ROIC=1.3%; FY2024: ROIC=-2.2%; FY2025: ROIC=3.2%
    ✗AkreLatest 3 consecutive FYs: ROIC > 15% in each
    Reinvestment Rate x ROIC3.2% (RR=100% x ROIC=3.2%)
    ✗AkreReinvestment Rate * ROIC > 10%
    ROIC (5-year)0/5 years above 12% (latest 3.2%)
    ✗SleepROIC > 12% in a majority of years
  • Valuation models0% pass✗ 11▾

    LGND overvalued: all 11 models price fair value below $308.79 (median $72.39)

    Graham fair value$83.88
    ✗Graham-268.1% margin vs $308.79
    Buffett fair value$93.50
    ✗Buffett-230.3% margin vs $308.79
    Lynch fair value$102.10
    ✗Lynch-202.4% margin vs $308.79
    Greenblatt fair value$4.01
    ✗Greenblatt-7600.5% margin vs $308.79
    Dreman fair value$44.25
    ✗Dreman-597.8% margin vs $308.79
    Munger fair value$44.68
    ✗Munger-591.1% margin vs $308.79
    Pabrai fair value$127.50
    ✗Pabrai-142.2% margin vs $308.79
    Akre fair value$59.12
    ✗Akre-422.3% margin vs $308.79
    Marks fair value$72.39
    ✗Marks-326.6% margin vs $308.79
    Ackman fair value$87.86
    ✗Ackman-251.5% margin vs $308.79
    Templeton fair value$30.54
    ✗Templeton-911.1% margin vs $308.79
  • Debt & Leverage8% pass✓ 1✗ 14▾

    11 of 12 flag LGND's debt & leverage — Graham, Buffett, Lynch +8 more

    LT Debt vs Net Current AssetsLT Debt $679.9M vs NCA $107.7M
    ✗GrahamLT Debt <= Net Current Assets
    Debt/Equity & Interest CoverageD/E: 1.17, IC: 2.9x
    ✗BuffettD/E < 0.5 AND Interest Coverage > 5x
    Total Debt / Equity1.17
    ✗Lynch< 0.33
    Cash - Long-term Debt$-624.0M
    ✗LynchPositive preferred
    LT Debt / Total Assets Change0.00% -> 0.00%
    ✓PiotroskiDecreased YoY
    Current Assets / Current Liabilities1.22
    ✗Dreman> 1.5✗SchlossCurrent ratio >= 1.50x (app cutoff)
    Total Debt / Shareholders' Equity1.17
    ✗Dreman< 0.8✗Templeton< 1.0 (fixed cap; proxy for below-sector-median leverage)✗SchlossD/E < 1.00x
    Debt Levels1.17
    ✗MungerDebt/Equity < 0.5✗AkreDebt/Equity < 0.3
    Interest Coverage & Debt/EBITDAIC=2.9x, D/EBITDA=19.1x
    ✗MarksInterest Coverage > 3x; Debt/EBITDA < 4x
    Total Debt / Shareholders Equity1.17
    ✗Ackman<= 1.0
    Negative debt-to-equity (higher means less debt)-1.1731; #3385/4210 (top 80.4%)
    ✗AsnessTop 30% of eligible cross-section
  • Verdicts14% pass✓ 2✗ 12▾

    Split decision: 11 FAIL · 3 NEUTRAL · 2 PASS

    Overall verdict
    ✗GrahamFAIL (1/9)✗BuffettFAIL (2/9)✗LynchFAIL (2/7)✗GreenblattRank #1774✓PiotroskiPASS (F-Score 5)✗DremanFAIL (2/11)✗MungerFAIL (0/4)✗PabraiFAIL (0/3)✗AkreFAIL (1/6)✗MarksFAIL (2/5)✓AckmanPASS (4/9)✗TempletonFAIL (3/8)•SleepNEUTRAL (4/6)•AsnessNEUTRAL (Not ranked)✗NeffFAIL (3/6)✗SchlossFAIL (1/7)•OshaughnessyNEUTRAL (Not ranked)
  • Profitability19% pass✓ 11✗ 24▾

    13 of 16 flag LGND's profitability — Graham, Buffett, Lynch +10 more

    Positive EPS (10 years)11/26 years positive
    ✗GrahamPositive EPS every year for 10 years
    EPS Growth (3-yr avg, 10-yr window)
    ✗Graham>= 33% growth
    Net Income Positive (10+ years)12/26 years positive
    ✗BuffettPositive every year for 10+ years
    ROE (up to 5-year arithmetic mean)4.1%
    ✗Buffett> 15% arithmetic mean (app rule)
    Operating Margin (10-yr trend)15.3% (latest)
    ✓BuffettStable or rising over 10 years
    Free Cash Flow Proxy$157.8M
    ✓BuffettPositive and growing
    Earnings Variance (10-yr CoV)
    ✗BuffettCoV < 0.3
    Retained Earnings Effectiveness
    ✗Buffett$1 retained -> > $1 market value created
    Basic earnings-growth PEG (dividends excluded)3.02
    ✗Lynch< 1.0 (ideally < 0.5)
    3-5 Year EPS CAGR16.7%
    ✓Lynch15-30% (Fast Grower); > 0% to pass
    ROE5.4%
    ✗Lynch> 15%
    EBIT / Enterprise Value0.3%
    ✗Greenblatt> 10%
    Earnings Yield + ROC AssessmentEY=0.3%, ROC=4.8%
    ✗GreenblattBoth EY > 10% and ROC > 25%
    Net Income / Total Assets7.97%
    ✓PiotroskiROA > 0
    ROA Change YoY-0.43% -> 7.97% (delta: +8.40%)
    ✓PiotroskiCurrent ROA > Prior ROA
    (CFO / Total Assets) vs ROACFO/Assets=3.16%, ROA=7.97%
    ✗PiotroskiCFO/Assets > ROA
    Gross Margin Change YoY
    ✗PiotroskiImproved YoY
    Pre-Tax Income / Revenue20.8%
    ✓Dreman>= 8%
    Net Income / Shareholders' Equity5.4%
    ✗Dreman> 12%
    Margin of SafetyP/E=50.4x, P/B=6.1x
    ✗PabraiP/B < 1.5 or P/E < 15
    Return on Equity6.4% (3-yr avg)
    ✗AkreROE > 20% (3-year avg)
    Discount to Intrinsic Value-597.8% (IV=$44.25 vs Price=$308.79)
    ✗Marks>= 20% below intrinsic value
    Positive Net Income Frequency12/19 years positive
    ✓MarksPositive net income in >= 7 of last 10 years
    Operating Income / Revenue9.5%
    ✗Ackman>= 15%
    Net Income / Shareholders Equity5.4%
    ✗Ackman>= 15%
    5-Year EPS CAGR16.7% CAGR over 4 years
    ✓Templeton> 0% (5-year EPS CAGR)
    Operating Margin Trend9.1% (2023) -> 15.3% (2025)
    ✓TempletonNon-negative operating-margin trend over 3 years
    Revenue growth vs. gross and operating margin trendrevenue up, operating margin 9.1% -> 15.3%
    ✓SleepRevenue rising; gross margin flat or falling; operating margin holding
    Net income / market capitalization+0.83%; #3022/6340 (top 47.7%)
    ✗AsnessTop 30% of eligible cross-section✗OshaughnessyTop 10% of eligible cross-section
    Gross profit / total assets
    ✗AsnessTop 30% of eligible cross-section
    Net income / positive book equity+5.35%; #2420/5226 (top 46.3%)
    ✗AsnessTop 30% of eligible cross-section
    Negative 5-year standard deviation of ROA-0.0460; #2466/5884 (top 41.9%)
    ✗AsnessTop 30% of eligible cross-section
    3-5 Year Diluted EPS CAGR16.7% over 4 years
    ✓Neff7%-20% annualized
    Positive Diluted-EPS Years6/10 years positive
    ✗Schloss>= 70% positive over 5-10 observed years (app rule)
  • Cash Flow50% pass✓ 6✗ 6▾

    5 of 10 pass — Piotroski, Dreman, Pabrai +2 more object

    Free Cash Flow Proxy$157.8M
    ✓BuffettPositive and growing
    FCF Positive and Growing$90.6M
    ✓LynchPositive and growing
    Operating Cash Flow$49.4M
    ✓PiotroskiCFO > 0
    (CFO / Total Assets) vs ROACFO/Assets=3.16%, ROA=7.97%
    ✗PiotroskiCFO/Assets > ROA
    Price / (CFO / Shares)124.8x
    ✗Dreman< 8x
    P/E or FCF YieldP/E=50.4x, FCF Yield=0.8%
    ✗PabraiP/E < 15 or FCF Yield > 10%
    FCF Positive12/17 years FCF positive
    ✓MarksPositive FCF in majority of recent years
    (OCF - CapEx) / Market Cap1.5%
    ✗Ackman>= 4%
    Price / FCF per Share125.9x
    ✗Ackman<= 25
    Positive Operating Cash Flow frequency16/20 years positive
    ✓SleepPositive OCF in >= 70% of available years
    Operating Cash Flow - Capital Expenditures$90.6M
    ✓Neff> $0 (app proxy for a strong fundamental case)
    (Operating cash flow - capex) / market capitalization+1.47%; #2330/4519 (top 51.6%)
    ✗OshaughnessyTop 10% of eligible cross-section

Business & financials

Financial snapshot: annual FY 2025. Current investor scores may use newer quarterly data.

Company Profile

Industry: Pharmaceutical Products
SIC Sector: Chemicals & Pharmaceuticals
Size: Mid Cap($6.2B)
Revenue: $268.1M+60.4% YoY
Net Income: $124.5M+3186.6% YoY

Financial Snapshot

Operating Margin15.3%
Return on Equity12.2%
Debt / Equity0.00
Current Ratio22.23
EPS (Diluted)$6.13
Buybacks (1y)$15.0M
Buybacks (2y)$15.0M
Shares Retired−3.6% / −12.6% 2y

Similar Companies

MRKMerck & Co., Inc.
$364.3B
ABTABBOTT LABORATORIES
$188.0B
BMYBRISTOL MYERS SQUIBB CO
$129.7B
TECHBIO-TECHNE Corp
$11.4B

Shareholder Return

Fiscal 2025

Issued 3.6% of shares last year, 12.6% issued over two.

Buybacks
$15.0M
Dividends
—

Company Financials

Latest TTM and quarters alongside annual years

TTM sums four consecutive quarters and uses the latest quarter-end balances. Quarter columns show three-month results; annual columns show full-year totals. Growth compares the same period a year earlier. EPS is not added for TTM; full-year ratios are blank for quarters.

The latest annual period end is unavailable. Showing the latest fiscal cycle’s quarters; quarter and annual columns may overlap. Quarterly shows the full quarter history.

MetricTTM · 2026-09-30

2025-10-01 – 2026-09-30

Sources · derived quarter values

Derived from cumulative filings: revenue, net income, operating income, ebit, pre tax income, interest expense, operating cash flow, depreciation amortization, capex, buybacks.

Q3 FY 2026

2026-07-01 – 2026-09-30

Sources · derived quarter values

Derived from cumulative filings: operating cash flow, depreciation amortization, capex, buybacks.

Q2 FY 2026

2026-04-01 – 2026-06-30

Sources · derived quarter values

Derived from cumulative filings: operating cash flow, depreciation amortization, capex.

Q1 FY 2026

2026-01-01 – 2026-03-31

Sources
FY 2025
Sources
  • 10-K · 2026-02-27
FY 2024
Sources
  • 10-K · 2025-02-28
FY 2023
Sources
  • 10-K · 2024-02-29
FY 2022
Sources
  • 10-K · 2023-02-28
FY 2021
Sources
  • 10-K · 2022-02-28
Market Cap$6.2Bcurrent------$3.8Best.$2.2Best.$1.3Best.$1.2Best.$1.3Best.
Revenue$253.8M↑1%$78.7M↓32%$63.7M↑34%$51.7M↑14%$268.1M↑60%$167.1M↑27%$131.3M↓33%$196.2M↓19%$241.5M
Operating Income$24.0M↑37%-$15.8M↓129%$8.6M↑2%$17.4M↑148%$41.0M↑281%-$22.6M↓289%$11.9M↑293%$3.0M↓97%$103.9M
Net Income$51.5M↑6%-$28.5M↓124%$48.5M↑901%-$13.3M↑69%$124.5M↑3187%-$4.0M↓108%$52.2M↑256%-$33.4M↓158%$57.1M
EPS (Diluted)--$-1.43↓125%$2.22↑825%$-0.67↑70%$6.13↑2886%$-0.22↓107%$2.94↑248%$-1.98↓160%$3.31
Gross Margin—————————
Operating Margin9.5%↑36%-20.0%↓142%13.5%↓24%33.6%↑142%15.3%↑213%-13.5%↓249%9.1%↑488%1.5%↓96%43.0%
ROE5.4%↑5%———12.2%↑2620%-0.5%↓107%7.4%↑233%-5.6%↓180%7.0%
Total Debt$1.1B$1.1B$1.1B↑4694042%--$50.0K↓32%$73.0K↑284%$19.0K↓100%$76.7M↓76%$320.7M
Shareholders' Equity$961.8M↑1%$961.8M↑1%$967.5M↑17%$997.3M↑25%$1.0B↑22%$830.4M↑18%$700.9M↑17%$597.5M↓27%$821.2M
Current Ratio1.22↓95%1.22↓95%31.18↑472%21.28↑304%22.23↑149%8.93↓37%14.15↑430%2.67↓76%11.15
Debt / Equity1.171.171.16↑4019712%—0.00↓44%0.00↑224%0.00↓100%0.13↓67%0.39
Operating Cash Flow$91.0M↑185%-$27.6M↓311%$24.0M↑52%$48.7M↑291%$49.4M↓49%$97.0M↑96%$49.6M↓64%$137.8M↑75%$78.8M
Free Cash Flow$90.6M↑195%-$27.7M↓312%$24.0M↑54%$48.5M↑289%$48.9M↓49%$95.2M↑107%$46.1M↓62%$119.9M↑71%$70.0M

Score history

Historical Score Timeline

Industry peers

Industry Peers

Similar companies in Pharmaceutical Products

LGND vs Peers — Financial Grading

Revenue$268.1MBottom 25%
Net Income$124.5MMedian
ROE12.2%Median
D/E0.00Top 25%
Op. Margin15.3%Median
Curr. Ratio22.23Top 25%
CompanyMarket CapPriceRevenueNet IncomeROED/EOp. MarginCurr. RatioGrahamBuffettLynchGreenblattPiotroskiDreman
Merck & Co., Inc.MRK$364.3B$147.76$65.0B$18.3B34.7%0.94—1.542/95/94/70/3F-Score 41/11
ABBOTT LABORATORIESABT$188.0B$108.52$44.3B$6.5B12.5%0.2518.2%1.583/94/92/71/3F-Score 53/11
BRISTOL MYERS SQUIBB COBMY$129.7B$63.43$48.2B$7.1B38.2%2.4419.4%1.262/91/93/71/3F-Score 85/11
BIO-TECHNE CorpTECH$11.4B$72.80$1.2B$73.4M3.8%—8.4%3.464/93/93/70/3F-Score 54/11
REPLIGEN CORPRGEN$10.7B$167.79$738.3M$48.9M2.3%0.267.5%8.373/92/93/70/3F-Score 75/11
IONIS PHARMACEUTICALS INCIONS$4.8B$29.06$943.7M$381.4M-78.0%3.60-40.4%3.833/91/91/70/3F-Score 43/11
NEOGEN CORPNEOG$2.5B$11.23$870.4M$7.9M-0.4%0.76-2.5%3.823/91/92/70/3F-Score 64/11
Pharvaris N.V.PHVS$2.4B$33.36—$206.4M-64.8%0.00——0/90/92/70/3F-Score 22/11